Matrix Capital Management led the immunology drug developer's series A round, which will support the journey of a type 1 diabetes drug candidate towards the clinic.

GentiBio, a US-based developer of immunology therapies based on findings from several research centres, has completed a $157m series A round led by investment manager Matrix Capital Management. The round included pharmaceutical firm Novartis, which invested through its Novartis Venture Fund, as well as Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management and Seattle…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.